Prognostic Value Estimation of Monoamines Systemic Level in Retinopathy of Prematurity in Experiment
The aim of the investigation was to study a systemic level of L-DOPA, dopamine, and norepinephrine, and assess their prognostic value in retinopathy of prematurity (ROP) development on an experimental disease model.
Materials and Methods. The investigation was carried out on infant Wistar rats (n=36) divided into a study group (rat infants with experimental ROP, n=17) and a control group (n=19). The animals of both groups were sacrificed on days 14, 21–23, and on days 28–30. The choice of the indicated periods corresponded to the key stages of ROP development in an experiment and was based on the findings of our previous histological studies. Dopamine, L-DOPA, and norepinephrine levels in infant rat blood plasma samples were determined.
Results. On day 14 of the experiment (the period corresponds to the pathological neovascularization induction in the applied model and preclinical ROP in children), mean L-DOPA level in infant rats with ROP (0.31 ng/ml) was significantly decreased compared to that in the controls (0.42 ng/ml) (p≤0.01). On days 21–23 of the experiment (the period corresponds to the growth of pathological extraretinal neovascularization in the applied model and ROP stage 3 in children) the systemic level of L-DOPA was still statistically reduced in the study group (0.87 ng/ml) compared to the control group (1.53 ng/ml) (p≤0.01). On days 28–30 of the experiment (the period corresponds to the regress of neovasculature in the applied model and a spontaneous ROP regress stage in children) the L-DOPA level in blood plasma in the study group (0.33 ng/ml) showed an insignificant upward tendency in reference to the controls (0.21 ng/ml). Mean dopamine and norepinephrine levels had no difference in the groups under study of infant rats within all follow-up periods.
Conclusion. Low systemic level of L-DOPA at the preclinical stage of experimental ROP should be considered as a laboratory prognostic criterion of a developing pathological process; it will enable to use the criterion when working out the measures to optimize the existing screening system for the disease in children.
- Yonekawa Y., Thomas B.J., Thanos A., Todorich B., Drenser K.A., Trese M.T., Capone A. Jr. The cutting edge of retinopathy of prematurity care: expanding the boundaries of diagnosis and treatment. Retina 2017; 37(12): 2208–2225, https://doi.org/10.1097/iae.0000000000001719.
- International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 2005; 123(7): 991–999, https://doi.org/10.1001/archopht.123.7.991.
- Grossniklaus H.E., Kang S.J., Berglin L. Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res 2010; 29(6): 500–519, https://doi.org/10.1016/j.preteyeres.2010.05.003.
- Barnett J.M., Yanni S.E., Penn J.S. The development of rat model of retinopathy of prematurity. Doc Ophthalmol 2010; 120(1): 3–12, https://doi.org/10.1007/s10633-009-9180-y.
- Katargina L.A., Osipova N.A., Panova A.J., Bondarenko N.S., Nikishina Yu. O., Murtazina A.R., Ugryumov M.V. Studying the pathogenic role of catecholamines in the development of retinopathy of prematurity on an experimental model of the disease. Rossijskij oftalʹmologiceskij zurnal 2019; 12(4): 64–69, https://doi.org/10.21516/2072-0076-2019-12-4-64-69.
- Katargina L.A., Osipova N.A., Panova A.Y., Petrovskaya A.V., Nikishina Yu.O., Murtazina A.R., Ugrumov M.V. The role of catecholamines in the development of pathological retina neovascularization in an experimental model of retinopathy of prematurity in rats. Doklady Akademii nauk 2019; 489(3): 313–317, https://doi.org/10.31857/s0869-56524893313-317.
- Katargina L.A., Khoroshilova-Maslova I.P., Majbogin A.M., Panova I.G., Osipova N.A. Pathomorphological features of the development of experimental retinopathy of prematurity. Mezdunarodnyj zurnal prikladnyh i fundamental’nyh issledovanij 2017; 3–2: 190–194.
- Assotsiatsiya vrachey-oftal’mologov: mezhregional’naya obshchestvennaya organizatsiya. Federal’nye klinicheskie rekomendatsii po diagnostike, monitoringu i lecheniyu aktivnoy fazy retinopatii nedonoshennykh [Association of ophthalmologists: interregional public organization. Federal clinical guidelines for the diagnosis, monitoring and treatment of the active phase of retinopathy of prematurity]. Moscow; 2013; 27 p.
- Quinn G.E., Ying G.S., Bell E.F., Donohue P.K., Morrison D., Tomlinson L.A., Binenbaum G.; G-ROP Study Group. Incidence and early course of retinopathy of prematurity: secondary analysis of the postnatal growth and retinopathy of prematurity (G-ROP) study. JAMA Ophthalmol 2018; 136(12): 1383–1389, https://doi.org/10.1001/jamaophthalmol.2018.4290.
- Chen J., Stahl A., Hellstrom A., Smith L.E. Current update on retinopathy of prematurity: screening and treatment. Curr Opin Pediatr 2011; 23(2): 173–178, https://doi.org/10.1097/mop.0b013e3283423f35.
- Spix N.J., Liu L.L., Zhang Z., Hohlbein J.P., Prigge C.L., Chintala S., Ribelayga C.P., Zhang D.Q. Vulnerability of dopaminergic amacrine cells to chronic ischemia in a mouse model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 2016; 57(7): 3047–3057, https://doi.org/10.1167/iovs.16-19346.
- Zhang N., Favazza T.L., Baglieri A.M., Benador I.Y., Noonan E.R., Fulton A.B., Hansen R.M., Iuvone P.M., Akula J.D. The rat with oxygen-induced retinopathy is myopic with low retinal dopamine. Invest Ophthalmol Vis Sci 2013; 54(13): 8275–8284, https://doi.org/10.1167/iovs.13-12544.
- Falk T., Congrove N.R., Zhang S., McCourt A.D., Sherman S.J., McKay B.S. PEDF and VEGF-A output from human retinal pigment epithelial cells grown on novel microcarriers. J Biomed Biotechnol 2012; 2012: 278932, https://doi.org/10.1155/2012/278932.
